Biomedical research organization IAVI has secured $36 million in funding as part of a potential $99 million U.S. government contract to develop a single-dose vaccine candidate targeting the Bundibugyo strain of the Ebola virus.
In Plain English: The Clinical Takeaway
- Single-Dose Efficacy: The vaccine candidate uses a vesicular stomatitis virus (rVSV) vector, which IAVI stated has shown protective efficacy in animal studies. Single-dose vaccines can offer practical benefits during outbreaks by enabling rapid immunization without the logistical requirements of a multi-dose schedule.
- Targeted Protection: There are currently no licensed vaccines or specific treatments for diseases caused by the Bundibugyo virus. The outbreak in the Democratic Republic of Congo is the largest and deadliest in the country’s history.
- Collaborative Manufacturing: IAVI is partnering with Hilleman Laboratories, SK bioscience, and IDT Biologika to collaborate on development, manufacturing, and vaccine production.
Funding and Vaccine Development Scope for Bundibugyo Ebola Strain
The biomedical research organization IAVI announced on Wednesday that it received $36 million in funding as part of a U.S. government contract with a volume of up to $99 million. This financial backing is dedicated to advancing the organization’s vaccine candidate against the Bundibugyo strain of the Ebola virus.
According to the government, confirmed Ebola cases in the Democratic Republic of Congo surpassed 10,000 on Tuesday. This makes the Bundibugyo outbreak the largest and deadliest in the country’s history. At present, there are no licensed vaccines or specific treatments for diseases caused by the Bundibugyo virus.
The funding from the U.S. Biomedical Advanced Research and Development Authority supports the manufacture of vaccine doses for clinical tests and outbreak response, including an early-stage study. It also supports the development of an updated candidate that targets the variant behind the 2026 Bundibugyo outbreak.
Consortium Partnerships and Immunological Mechanism
IAVI will collaborate on development, manufacturing, and vaccine production with Hilleman Laboratories, SK bioscience, and IDT Biologika.
IAVI stated that its rVSV-based single-dose vaccine candidate has shown protective efficacy in animal studies. Single-dose vaccines can offer practical benefits during outbreaks, as they allow for rapid immunization without having to meet the logistical requirements of a multi-dose schedule.
Pharmaceutical Supply Updates and Outbreak Logistics
The pharmaceutical manufacturer Regeneron stated on Monday that it has extended its agreement with the U.S. health authority regarding the supply of additional quantities of its Ebola medication.
| Entity / Organization | Action / Initiative | Financial / Supply Detail |
|---|---|---|
| IAVI | Developing rVSV single-dose vaccine for Bundibugyo Ebola | $36M funding (up to $99M total contract) |
| Regeneron | Extending therapeutic supply agreement with U.S. health authorities | Additional quantities of Ebola medication |
| Democratic Republic of Congo Government | Monitoring epidemic spread | Exceeded 10,000 confirmed cases |
Contraindications & When to Consult a Doctor
The IAVI vaccine candidate is in development.
References
- IAVI announcement.
- On Cloudsurfer 3 Review: The Brand’s Softest Running Shoe Yet
- South Korea to Invest 2.7 Trillion Won to Boost Regional and Essential Medical Insurance Fees
- $3,400 Student Funding Reduction in Mainstream Classrooms Announced (newsy-today.com)
- How Congo's Ebola Trial Uses a Typhoid Shot to Test Ervebo (daybreakwire.com)
